HUP0002713A3 - 8-azabicyclo[3,2,1]oct-2-ene and octane derivatives, process for preparation thereof, pharmaceutical compositions comprising thereof and their use - Google Patents

8-azabicyclo[3,2,1]oct-2-ene and octane derivatives, process for preparation thereof, pharmaceutical compositions comprising thereof and their use

Info

Publication number
HUP0002713A3
HUP0002713A3 HU0002713A HUP0002713A HUP0002713A3 HU P0002713 A3 HUP0002713 A3 HU P0002713A3 HU 0002713 A HU0002713 A HU 0002713A HU P0002713 A HUP0002713 A HU P0002713A HU P0002713 A3 HUP0002713 A3 HU P0002713A3
Authority
HU
Hungary
Prior art keywords
azabicyclo
ene
oct
preparation
pharmaceutical compositions
Prior art date
Application number
HU0002713A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Neurosearch As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch As filed Critical Neurosearch As
Publication of HUP0002713A2 publication Critical patent/HUP0002713A2/hu
Publication of HUP0002713A3 publication Critical patent/HUP0002713A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
HU0002713A 1997-05-30 1998-05-29 8-azabicyclo[3,2,1]oct-2-ene and octane derivatives, process for preparation thereof, pharmaceutical compositions comprising thereof and their use HUP0002713A3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DK62797 1997-05-30
DK150297 1997-12-19
DK40898 1998-03-24
DK53498 1998-04-16

Publications (2)

Publication Number Publication Date
HUP0002713A2 HUP0002713A2 (hu) 2001-01-29
HUP0002713A3 true HUP0002713A3 (en) 2001-02-28

Family

ID=27439314

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0002713A HUP0002713A3 (en) 1997-05-30 1998-05-29 8-azabicyclo[3,2,1]oct-2-ene and octane derivatives, process for preparation thereof, pharmaceutical compositions comprising thereof and their use

Country Status (22)

Country Link
US (2) US6645977B1 (cg-RX-API-DMAC7.html)
EP (1) EP0984965B1 (cg-RX-API-DMAC7.html)
JP (1) JP4447663B2 (cg-RX-API-DMAC7.html)
KR (1) KR100589872B1 (cg-RX-API-DMAC7.html)
CN (1) CN1157392C (cg-RX-API-DMAC7.html)
AT (1) ATE267199T1 (cg-RX-API-DMAC7.html)
AU (1) AU745964B2 (cg-RX-API-DMAC7.html)
BR (1) BR9809697A (cg-RX-API-DMAC7.html)
CA (1) CA2289574C (cg-RX-API-DMAC7.html)
CZ (1) CZ298824B6 (cg-RX-API-DMAC7.html)
DE (1) DE69823994T2 (cg-RX-API-DMAC7.html)
DK (1) DK0984965T3 (cg-RX-API-DMAC7.html)
EE (1) EE04057B1 (cg-RX-API-DMAC7.html)
HU (1) HUP0002713A3 (cg-RX-API-DMAC7.html)
IL (2) IL132437A0 (cg-RX-API-DMAC7.html)
IS (1) IS2092B (cg-RX-API-DMAC7.html)
NO (1) NO325513B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ500642A (cg-RX-API-DMAC7.html)
RU (1) RU2186780C2 (cg-RX-API-DMAC7.html)
SK (1) SK284994B6 (cg-RX-API-DMAC7.html)
TR (1) TR199902942T2 (cg-RX-API-DMAC7.html)
WO (1) WO1998054181A1 (cg-RX-API-DMAC7.html)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998024788A1 (en) * 1996-12-02 1998-06-11 Georgetown University Tropane derivatives and method for their synthesis
WO1999065492A1 (en) 1998-06-19 1999-12-23 Eli Lilly And Company Inhibition of serotonin reuptake
US6218383B1 (en) * 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
DE69914935T2 (de) * 1998-11-27 2009-10-01 Neurosearch A/S 8-azabicyclo[3.2.1]okt-2-en- und -oktanderivate
US6432975B1 (en) * 1998-12-11 2002-08-13 Targacept, Inc. Pharmaceutical compositions and methods for use
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
EP1149095B1 (en) * 1999-01-28 2004-01-21 Neurosearch A/S Novel azabicyclo derivatives and their use
EP1147112B1 (en) * 1999-01-29 2003-10-29 Abbott Laboratories Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands
US7265115B2 (en) 1999-01-29 2007-09-04 Abbott Laboratories Diazabicyclic CNS active agents
NZ513575A (en) * 1999-05-04 2003-07-25 Neurosearch As Heteroaryl diazabicycloalkanes useful for treating or preventing a disease or a disorder responsive to the activity of nAChR modulators
US6890935B2 (en) 1999-11-01 2005-05-10 Targacept, Inc. Pharmaceutical compositions and methods for use
MY145722A (en) * 2000-04-27 2012-03-30 Abbott Lab Diazabicyclic central nervous system active agents
ATE287888T1 (de) * 2000-07-04 2005-02-15 Neurosearch As Aryl- und heteroaryldiazabicycloalkane, deren zubereitung und verwendung
EP1358177B1 (en) * 2000-10-13 2006-08-02 NeuroSearch A/S Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance
CZ2004408A3 (cs) * 2001-10-02 2005-03-16 Pharmacia & Upjohn Company Azabicyklicky substituované kondenzované heteroarylsloučeniny
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
JP2005523288A (ja) 2002-02-19 2005-08-04 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 疾病治療用の縮合した二環式−n−架橋−複素環式芳香族カルボキサミド
AU2003222738B2 (en) 2002-05-07 2009-09-17 Neurosearch A/S Novel azacyclic ethynyl derivatives
GB2398636A (en) * 2003-02-21 2004-08-25 Ipsen Ltd Method for determining the quantity of pre-synaptic neuromuscular blocking substance contained in a sample
EP1601664B1 (en) * 2003-02-28 2008-04-30 Schering Corporation Biaryltetrahydroisoquinoline piperidines as selective mch receptor antagonists for the treatment of obesity and related disorders
BRPI0408248A (pt) 2003-03-12 2006-03-01 Pfizer Prod Inc derivados azabicìclicos de piridiloximetila e de benzisoxazol
US20070191815A1 (en) 2004-09-13 2007-08-16 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery
US20060173037A1 (en) * 2005-01-10 2006-08-03 Nathalie Schlienger Aminophenyl derivatives as selective androgen receptor modulators
DE602006019561D1 (de) 2005-02-16 2011-02-24 Neurosearch As Diazabicyclische arylderivate und ihre verwendung als chinolinergische liganden an nikotin-acetylcholin-rezeptoren
DE102005007859A1 (de) * 2005-02-21 2006-08-24 Lts Lohmann Therapie-Systeme Ag Vefahren für eine medikamentöse Kombinations-Behandlung, sowie hierfür geeignete Arzneimittel-Kombinationen
AU2006233884A1 (en) * 2005-04-08 2006-10-19 Neurosearch A/S (+) - and (-) -8-alkyl-3-(trifluoralkylsulfonyloxy)-8-azabicycl (3.2.1.)oct-2-ene
FR2889701B1 (fr) * 2005-08-12 2007-10-05 Sanofi Aventis Sa Derives de 5-pyridinyl-1-azabicyclo[3.2.1]octane, leur preparation en therapeutique.
CA2632642A1 (en) 2005-12-06 2007-06-14 Neurosearch A/S Novel diazabicyclic aryl derivatives and their medical use
US20070134169A1 (en) * 2005-12-11 2007-06-14 Rabinoff Michael D Methods for smoking cessation or alcohol cessation or other addiction cessation
US7687523B2 (en) 2006-02-10 2010-03-30 Neurosearch A/S 3-heteroaryl-3,9-diazabicyclo[3.3.1]nonane derivatives as nicotinic acetylcholine receptor agonists
EP1984365A1 (en) 2006-02-10 2008-10-29 NeuroSearch A/S 3,9-diazabicyclo[3.3.1]nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
WO2007090887A1 (en) 2006-02-10 2007-08-16 Neurosearch A/S 3, 9-diazabicyclo [3.3. 1]nonane derivatives and their use as monoamine?neurotransmitter re-uptake inhibitors
KR20090013827A (ko) * 2006-06-12 2009-02-05 화이자 프로덕츠 인크. Hiv 환자에서 면역 재구성을 증진시키고 기회 감염을 치료하기 위한 ccr5 길항제
EP1977746B8 (en) 2007-04-02 2014-09-24 Parkinson's Institute Methods and compositions for reduction of side effects of therapeutic treatments
TWI415850B (zh) * 2007-07-20 2013-11-21 Theravance Inc 製備mu類鴉片受體拮抗劑之中間物的方法
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
US8697722B2 (en) * 2007-11-02 2014-04-15 Sri International Nicotinic acetylcholine receptor modulators
JP5421368B2 (ja) * 2008-08-01 2014-02-19 パーデュー、ファーマ、リミテッド、パートナーシップ テトラヒドロピリジニルおよびジヒドロピロリル化合物およびそれらの使用
CN102216295A (zh) * 2008-11-18 2011-10-12 神经研究公司 8-氮杂双环[3.2.1]辛-2-烯衍生物及其作为单胺神经递质再摄取抑制剂的用途
HUE026815T2 (en) 2008-11-19 2016-07-28 Forum Pharmaceuticals Inc Treatment of Cognitive Disorders with (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
AU2010247835A1 (en) * 2009-05-11 2011-12-08 Envivo Pharmaceuticals, Inc. Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptors in combination with acetylcholinesterase inhibitors
WO2011085389A1 (en) * 2010-01-11 2011-07-14 Astraea Therapeutics, Llc Nicotinic acetylcholine receptor modulators
TWI519532B (zh) 2010-05-17 2016-02-01 艾維沃製藥公司 (R)-7-氯-N-(啶-3-基)苯並[b]噻吩-2-羧醯胺鹽酸鹽單水合物之結晶形體
RU2017136693A (ru) 2012-05-08 2019-02-08 Форум Фармасьютикалз, Инк. Способы поддержания, лечения или улучшения когнитивной функции
WO2014011768A1 (en) * 2012-07-10 2014-01-16 Adispell, Inc. Anti-anxiety treatment
US10105487B2 (en) 2013-01-24 2018-10-23 Chrono Therapeutics Inc. Optimized bio-synchronous bioactive agent delivery system
JP2018511355A (ja) 2015-01-28 2018-04-26 クロノ セラピューティクス インコーポレイテッドChrono Therapeutics Inc. 薬剤送達方法及びシステム
US9724340B2 (en) 2015-07-31 2017-08-08 Attenua, Inc. Antitussive compositions and methods
WO2018129304A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
AU2019279884B2 (en) 2018-05-29 2025-01-30 Morningside Venture Investments Limited Drug delivery methods and systems
JP2022507660A (ja) 2018-11-16 2022-01-18 モーニングサイド ベンチャー インベストメンツ リミテッド 温度によって調節される経皮薬剤送達システム
KR102272452B1 (ko) 2020-12-11 2021-07-05 (주)예광솔라 스파이럴 파일 공법 및 이에 적용되는 스파이럴 파일
KR200497569Y1 (ko) 2021-02-18 2023-12-21 주식회사 알파인랩 지주 기초용 스크루 파일

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133073A (en) * 1959-12-10 1964-05-12 Sterling Drug Inc 3-aryl-1, 5-iminocycloalkanes and preparation thereof
US3657257A (en) * 1970-08-31 1972-04-18 Robins Co Inc A H 3-aryl-8-carbamoyl nortropanes
CA1244028A (en) 1983-04-14 1988-11-01 Hans Maag Pyrimidine derivatives
GB9019973D0 (en) 1990-09-12 1990-10-24 Wyeth John & Brother Ltd Azabicyclic derivatives
US5045546A (en) 1990-10-26 1991-09-03 Hoechst-Roussel Pharmaceuticals Inc. 8-azabicyclo[3.2.1]octylalkylthiazolidines
NZ241481A (en) 1991-02-04 1994-06-27 Hoechst Roussel Pharma Derivatives of 8-aza-bicyclo[3.2.1]octane and pharmaceutical compositions thereof
JP3153551B2 (ja) * 1991-05-29 2001-04-09 アボツト・ラボラトリーズ 認識機能を高めるイソオキサゾールおよびイソチアゾール化合物
US5731317A (en) * 1995-03-10 1998-03-24 Merck & Co., Inc. Bridged piperidines promote release of growth hormone
GB9507203D0 (en) * 1995-04-07 1995-05-31 Smithkline Beecham Plc Novel compounds
EP0853621A1 (en) * 1995-09-22 1998-07-22 Novo Nordisk A/S Novel substituted azacyclic or azabicyclic compounds
HUP9802433A3 (en) * 1995-10-13 2000-03-28 Neurosearch As 8-azabicyclo[3.2.1]oct-2-ene derivatives, their preparation and use
GB9706222D0 (en) * 1997-03-26 1997-05-14 Zeneca Ltd Bicyclic amine derivatives
EP0955301A3 (en) 1998-04-27 2001-04-18 Pfizer Products Inc. 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors
WO1999065492A1 (en) * 1998-06-19 1999-12-23 Eli Lilly And Company Inhibition of serotonin reuptake

Also Published As

Publication number Publication date
US6645977B1 (en) 2003-11-11
EE9900529A (et) 2000-06-15
JP2002501514A (ja) 2002-01-15
DK0984965T3 (da) 2004-09-27
JP4447663B2 (ja) 2010-04-07
IL132437A0 (en) 2001-03-19
HK1027353A1 (en) 2001-01-12
EE04057B1 (et) 2003-06-16
SK162699A3 (en) 2000-07-11
DE69823994D1 (de) 2004-06-24
WO1998054181A1 (en) 1998-12-03
DE69823994T2 (de) 2009-09-24
AU745964B2 (en) 2002-04-11
TR199902942T2 (xx) 2000-04-21
RU2186780C2 (ru) 2002-08-10
SK284994B6 (sk) 2006-04-06
AU7426198A (en) 1998-12-30
IS5243A (is) 1999-11-10
NO995850D0 (no) 1999-11-29
CZ298824B6 (cs) 2008-02-20
IS2092B (is) 2006-04-12
HUP0002713A2 (hu) 2001-01-29
CA2289574A1 (en) 1998-12-03
US20040019207A1 (en) 2004-01-29
US6964972B2 (en) 2005-11-15
KR100589872B1 (ko) 2006-06-15
EP0984965A1 (en) 2000-03-15
NO325513B1 (no) 2008-05-26
ATE267199T1 (de) 2004-06-15
KR20010013154A (ko) 2001-02-26
EP0984965B1 (en) 2004-05-19
NZ500642A (en) 2001-11-30
IL132437A (en) 2006-12-10
CN1257499A (zh) 2000-06-21
BR9809697A (pt) 2000-07-11
CZ414799A3 (cs) 2000-02-16
CN1157392C (zh) 2004-07-14
NO995850L (no) 1999-11-29
CA2289574C (en) 2007-04-24

Similar Documents

Publication Publication Date Title
AP9901556A0 (en) Sulpponamide derivatives process for their preparation and their use as medicaments
HUP9602122A3 (en) Camptothecin derivatives, process for the preparation thereof and pharmaceutical compositions containing them
HUP9900974A3 (en) Heterocycle-condensed morphinoid derivatives, process for the preparation thereof, their use and pharmaceutical compositions containing them
HUP9800138A3 (en) 8-substituted-1,3,8-triaza-spiro [4,5]-decan-4-on derivatives, process for producing them, pharmaceutical compositions containing the same and their use
HUP9802433A3 (en) 8-azabicyclo[3.2.1]oct-2-ene derivatives, their preparation and use
HUP0001508A3 (en) 4-arylmethylene-2-imino-2,3-dihydrothiazole derivatives, their use, process for the preparation thereof and pharmaceutical compositions containing them
HUP9700358A3 (en) New oxazolidinon derivatives, process for their preparation and pharmaceutical compositions containing them
IL112384A0 (en) Tetracyclic derivatives, their preparation and pharmaceutical compositions containing them
HUP0000562A3 (en) Fused pyrazole derivatives, process for their preparation, their use and pharmaceutical compositions containing them
ZA9810490B (en) 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor
HUP0204515A3 (en) 4-aminopiperidine derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUT76286A (en) Quinoline derivatives, pharmaceutical compositions containing them, process for producing them and their use
HUP0100280A3 (en) Pyrrolo-, thieno-, furano- and pyrazolo- [3,4d]-pyridazinones, process for their preparation and pharmaceutical compositions containing them
HUP0002480A3 (en) Pyrrolo[2,1-c][1,4]benzodiazepine derivatives, their use, process for their preparation and pharmaceutical compositions containing them
HUP0001555A3 (en) Tetrahydro-imidazo-naphthyridine derivatives, pharmaceutical compositions thereof and process for their preparation
HUP0000426A3 (en) Novel benzonaphthyridines, pharmaceutical compositions and use thereof and process for their preparation
HUP9901613A3 (en) Substituted tetracyclic fused furanamine derivatives, process for their preparation, use thereof and pharmaceutical compositions containing them
HUP9702400A3 (en) Substituted camptothecin derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0002300A3 (en) Quinoline-4-carboxamide derivatives, process for producing them, pharmaceutical compositions containing them and their use
HUP0202624A3 (en) Pyrazolo[4,3-d]pyrimidine-derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP9900987A3 (en) Camptothecin derivatives process for their preparation, use thereof as antitumor agents and pharmaceutical compositions containing them
HUP0003577A3 (en) Tetrahydro gamma-carbolines, process for their preparation, their use and pharmaceutical compositions containing them
HUP9901485A3 (en) Heterocyclylcarboxamide derivatives, pharmaceutical compositions containing the same, process for their preparation and their use
HUP9904514A3 (en) 5h-pyrrolo[2,1-c][1,4]-benzodiazepin 3-carboxamide derivatives, process for their preparation, their use and pharmaceutical compositions containing them
HUP0002650A3 (en) 4-oxo-3,5-dihydro-4h-pyridazino[4,5-b]-indole-1-acetamide derivatives, process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished